MEIP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (22 Apr 2024 @ 16:00):

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer...

Stats
Today's Volume	6 477.00
Average Volume	21 800.00
Market Cap	22.45M
EPS	$0 ( 2024-02-08 )
Next earnings date	( $-1.380 ) 2024-05-09
Last Dividend	$1.750 ( 2023-11-16 )
Next Dividend	$0 ( N/A )
P/E	1.130
ATR14	$0.0350 (1.04%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-18	Flynn James P	Buy	10 000	Stock Option (Right to Buy)
2023-12-18	Flynn James P	Buy	6 700	Stock Option (Right to Buy)
2023-12-18	Wood Steven D	Buy	10 000	Stock Option (Right to Buy)
2023-12-18	Wood Steven D	Buy	6 700	Stock Option (Right to Buy)
2023-12-18	Wood Steven D	Buy	10 000	Stock Option (Right to Buy)

INSIDER POWER
93.24
Last 96 transactions
Buy: 9 932 993 \| Sell: 849 643

MEI Pharma Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MEI Pharma Inc Financials

Annual	2023
Revenue:	$48.82M
Gross Profit:	$47.00M (96.28 %)
EPS:	$-4.78

Q4	2023
Revenue:	$1.46M
Gross Profit:	$993 000 (68.15 %)
EPS:	$-1.510

Q3	2023
Revenue:	$5.89M
Gross Profit:	$5.44M (92.25 %)
EPS:	$-2.17

Q2	2023
Revenue:	$32.74M
Gross Profit:	$32.29M (98.64 %)
EPS:	$1.540

Financial Reports:

No articles found.

MEI Pharma Inc Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$1.750 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

MEI Pharma Inc Dividend Information - Dividend King

Dividend Sustainability Score: 5.95 - average (65.44%) | Divividend Growth Potential Score: 1.097 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$1.750	2023-11-16
Last Dividend	$1.750	2023-11-16
Next Dividend	$0	N/A
Payout Date	2023-12-06
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$1.750	--
Avg. Dividend % Per Year	11.67%	--
Score	5.07	--
Div. Sustainability Score	5.95
Div.Growth Potential Score	1.097
Div. Directional Score	3.53	--

Next Divdend (Est)
(2024-04-23)

$3.50 Estimate 2.50 %

Dividend Stability

0.20 Very Poor

Dividend Score

5.07

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2023	$1.750	35.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.286	1.500	4.27	6.41	[0 - 0.5]
returnOnAssetsTTM	0.265	1.200	1.173	1.408	[0 - 0.3]
returnOnEquityTTM	0.416	1.500	6.49	9.73	[0.1 - 1]
payoutRatioTTM	0.561	-1.000	4.39	-4.39	[0 - 1]
currentRatioTTM	8.23	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.40	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	0.644	1.500	7.54	10.00	[0.2 - 2]
debtRatioTTM	0.153	-1.500	7.45	-10.00	[0 - 0.6]
interestCoverageTTM	-16.44	1.000	-7.20	-7.20	[3 - 30]
operatingCashFlowPerShareTTM	-7.95	2.00	-2.65	-5.30	[0 - 30]
freeCashFlowPerShareTTM	-7.95	2.00	-3.97	-7.95	[0 - 20]
debtEquityRatioTTM	0.202	-1.500	9.19	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.980	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.219	1.000	7.63	7.63	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-4.40	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.925	0.800	7.17	5.73	[0.5 - 2]
Total Score				5.95

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	1.205	1.000	9.98	0	[1 - 100]
returnOnEquityTTM	0.416	2.50	7.74	9.73	[0.1 - 1.5]
freeCashFlowPerShareTTM	-7.95	2.00	-2.65	-7.95	[0 - 30]
dividendYielPercentageTTM	93.09	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-7.95	2.00	-2.65	-5.30	[0 - 30]
payoutRatioTTM	0.561	1.500	4.39	-4.39	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.729	1.000	-10.00	0	[0.1 - 0.5]
Total Score				1.097

MEI Pharma Inc

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.